Filing Flows › Ideaya Biosciences (IDYA) › Q3 2025
Ideaya Biosciences (IDYA) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 4, 2025
Ideaya Biosciences (IDYA) reported revenue of $208M for the third quarter 2025 (Q3 2025). Operating margin was 52.2%, net earnings $119M (57.4% of revenue).
Ideaya Biosciences, Q3 2025: revenue $208M, operating margin 52.2%, net earnings $119M, operating cash flow $142M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $208M | — | — |
| Operating profit | $108M | — | — |
| Net earnings | $119M | — | — |
| Operating cash flow | $142M | — | — |
| Free cash flow | $142M | — | — |
What changed
Revenue was $207.8M in Q3 2025.
Operating profit was $108.5M, a 52.2% margin. Net earnings were $119.2M. The effective tax rate was 0.0%.
Operating cash flow was $142.2M, 119% of net earnings. Non-cash charges added back $661K of depreciation and amortization and $12.2M of share-based compensation. Working capital and other items added $10.1M. Capital expenditures of $42K left free cash flow of $142.2M.
Questions
What was Ideaya Biosciences' revenue in the third quarter 2025?
Ideaya Biosciences (IDYA) reported revenue of $208M for the third quarter 2025 (Q3 2025).
Was Ideaya Biosciences profitable in the third quarter 2025?
Operating profit was $108M (52.2% of revenue) and net earnings $119M.
Source: Ideaya Biosciences 10-Q on SEC EDGAR.